Stéphane Boissel, CEO of TxCell, joins Sangamo as Executive Vice President, Corporate Strategy RICHMOND, Calif. and VALBONNE, France , Oct. 1, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO)  and TxCell S.A. (ENXTPA: TXCL) today jointly announced the completion by Sangamo of the

RICHMOND, Calif. , Sept. 24, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that management will participate in the following healthcare investor and industry conferences in September and October. 2018 Jefferies Gene Therapy Summit, New York , NY, September 27, 2018

SSIEM presentation included early data from Cohorts 1 (low dose) and 2 (mid dose); enrollment of Cohort 3 (high dose, 5x the mid dose) was recently completed Total urinary GAGs declined by 51%, dermatan sulfate by 32%, and heparan sulfate by 61% in Cohort 2 at 16 weeks SB-913 has been generally

RICHMOND, Calif. , Aug. 30, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that management will host a conference call on September 5 th at 9:00 a.m. ET to discuss clinical data from the CHAMPIONS Study, the Company's Phase 1/2 trial evaluating SB-913 in vivo genome

RICHMOND, Calif. , Aug. 10, 2018 /PRNewswire/ --  Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that management will present a corporate overview at the 2018 Wedbush PacGrow Healthcare Conference in New York City . The presentation is scheduled for Tuesday, August 14 th at 4:15 p.m.

RICHMOND, Calif., Aug. 8, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced positive preliminary data from the Phase 1/2 clinical trial evaluating SB-525, a cDNA gene therapy candidate for Hemophilia A (the "Alta study"). SB-525 is being developed as part of a global

Company Also Separately Announced Positive Preliminary Data from Phase 1/2 Clinical Trial Evaluating SB-525 Gene Therapy for Hemophilia A Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time Today RICHMOND, Calif. , Aug. 8, 2018 /PRNewswire/ --  Sangamo Therapeutics, Inc.

RICHMOND, Calif. , Aug. 2, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that the Company will release its second quarter 2018 financial results after the market closes on Wednesday, August 8, 2018 . The press release will be followed by a conference call at 5:00

RICHMOND, Calif., July 31, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that preliminary safety and efficacy data from the CHAMPIONS Study, a Phase 1/2 clinical trial evaluating SB-913 for the treatment of mucopolysaccharidosis Type II (MPS II, also known as Hunter

Dr. Muenzer to review MPS II biology, standard of care, and rationale for the development of SB-913, an investigational genome editing treatment Webcast is scheduled for 2 p.m. ET on Wednesday, August 1, 2018 RICHMOND, Calif. , July 27, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc.